Asthma UK Annual General Meeting 3 July 2018
Agenda Presentations Formal AGM business ▪ Review of 2016 – 17 ▪ Apologies ▪ Digital Health ▪ Minutes from 2017 AGM ▪ Individual Giving ▪ Annual Report ▪ Financial review ▪ Auditors ▪ Trustees
Highlights of 2016 - 17 Kay Boycott Chief Executive
Our mission: Stop asthma attacks. Cure asthma. CAMPAIGN FOR CHANGE ON THE ISSUES PROVIDE EXPERT ADVICE AND FUND WORLD-CLASS RESEARCH THAT AFFECT PEOPLE WITH ASTHMA SUPPORT We have invested over £50 million in asthma research to date We constantly challenge complacency around asthma so We help people to effectively manage their daily life We fund scientists to pursue new avenues of research into that everyone knows just how serious asthma is with asthma asthma and develop better treatments We campaign and raise awareness of the issues and We achieve this by providing access to the best New technologies and better collaboration will increase the solutions so everyone gets the right basic care that information and practical advice available through chances of scientific breakthroughs . Ultimately a cure that research has proved substantially reduces the risk of an our website and our expert asthma nurse helpline would transform the lives of people with asthma will be found asthma attack We are determined that everyone with asthma will benefit We help people with asthma speak directly to politicians from scientific breakthroughs and decision makers on the issues that are important to them
How we are making a difference: In the last year, Asthma UK has… ➢ Supported over 1.8 million users on our website – an increase of 27% from last year ➢ Enabled 93,000 Asthma Action Plans to be downloaded – 71,000 of these for adults and 21,000 for children ➢ Selected as 1 of 4 ‘launch’ charities to use Facebook Pay ➢ Made the most from every donation : for every £1 spent …. 31.5p was reinvested in fundraising to make another £1 and 68.5p was spent on charitable activity ➢ Grown our social media channels by 20% (based year on year) ➢ Engaged with 30,000 Facebook users as part of our ‘back to school campaign’ and our pollen campaign reached 300,000 on social channels ➢ Helped 7367 people through our helpline whilst our nurses answered 7000 calls…. at the same time as delivering popular asthma Q&A sessions on social media! ➢ Published the Annual Asthma Survey 2017 , with 7611 responses – the largest AUK has ever seen! ➢ Successfully campaigned for the use of Mepolizumab and Reslizumab in the NHS ➢ Launched our Smart Asthma report as well as the 2016 – 2021 Research Strategy and the Research Roadmap ➢ Renewed our investment in the Basic Centre for another 5 years ➢ Funded 2 Fellows at Imperial College ➢ Co-funded £100,000 into the Epigenetics project (in partnership with LifeArc)
Research: ‘stand on the shoulders of giants’
2016 – 17 advances in scientific knowledge (funded through AUK research) Dr Henry McSorley has uncovered novel means to target a cytokine called IL-33, which is strongly implicated in causing asthma; this discovery promises exciting new opportunities for intervention in asthma Dr Anna Furmanski tested the idea of controlling the amount of Hedgehog (Hh) proteins (which cause inflammation in the lungs) to minimise allergic immune responses in asthma; a promising new idea for potential asthma treatments Prof. Ian Sayers and his team have identified the main genetic changes in the IL-33 and ST- 2 genes that are relevant to asthma; paving the way to understanding the changes and targeting them for therapy to correct the change Prof. Salman Siddiqui has found different types of asthma pathology using new data analysis techniques, allowing them to separate different types of airways pathology for people with mild, moderate and severe asthma Dr Hans Michael Haitchi (researching ADAM-33 a susceptibility gene that is associated with asthma) and his team have studied the effects caused by changes in ADAM-33 very early in life; leading to discoveries about the ways in which airways are prone to developing asthma when exposed to house dust mite allergen, at a very early stage in life
2016 – 17 advances in scientific knowledge (funded through AUK research) Dr Rachel Clifford has identified several genes that are particularly interesting in airway muscle cells & examined these for changes in DNA and gene signalling Prof. Hannah Gould and her team compared the gene expression signatures (which genes are ‘on’ and which are ‘off’) of cells that produce IgE antibodies; leading to potential new discoveries for targeting intervention in the development and progression of asthma Dr Tara Sutherland has succeeded in establishing a ‘mouse model’ of allergic inflammation and the factors assumed to play a role in humans; future work will look at changes in lung structure Dr Hannah Durrington has continued her work on understanding why asthma varies so much over the course of a day, this data has been presented as a talk at the European Biological Rhythms Society meeting (July 2017) Prof. Andrew Wardlaw and his Asthma UK funded PhD student have continued their work exploring the relationship between fungal allergy and lung damage. Their results could have major implications for treating fungal allergy in asthma Dr Amanda Tatler and the team have developed methods to perform key experiments on human tissue to compare responses between asthmatic and non-asthmatic breathing
Asthma UK 2017 – 2020: strategy Delivering charitable purpose Managing resources responsibly Activity 2017 – 2020 Strategy Activity 2017 – 2020 Strategy Inspire people with asthma to make a positive change Improve asthma Develop a sustainable asthma Re-imagine asthma management income generation model for a self-management through Maximise wherever digital world digital innovation resources for the delivered Pursue improvement in the NHS long-term for people with asthma benefit of people with Broker ambitious research Speed up asthma collaborations research against Advance Asthma UK’s agility and the biggest productivity Invest in exceptional asthma priorities patient-centric science
Digital health Emma Rubach Advice & Content Manager, Digital Health
Our risk checker engaged new people 50% increase in people using the risk checker tool Cross-selling the risk checker with our lottery audience has proved successful. After completing the checker people also have the option to sign up to get more email advice from us.
Social media health activation campaigns 30,000 Facebook Our pollen campaign users watched reached almost 300,000 on our ‘Back to social channels School’ campaign video, warning parents of the spike in asthma attacks in September
Increasing the reach of our Helpline nurses Answering people Appearing on with asthma’s instructional and questions on advice videos Facebook and This video on cleaning your Twitter spacer has had 12,600 views on YouTube Supporting people through the pilot of our 12-Week Asthma Support Programme
Individual Giving Joe Aldrich Direct Marketing Manager, Fundraising
INDIVIDUAL GIVING REGULAR GIVING CASH APPEALS & MAGAZINES STEWARDSHIP RAFFLES & LOTTERY
Raising £1.8M a year
INDIVIDUAL GIVING – Cause led growth GROSS INCOME* £1.02M 5% growth year on year NET INCOME* £831K 9% growth year on year *All figures up to the end of May 18
INDIVIDUAL GIVING – Cause led growth 2017/18 Gross Income Net Income 2016/17 XMAS APPEAL £48.6K £32.5K 35% net growth year on year SPRING RAFFLE £44.5K £17K 12% net growth year on year 2015/16 2016/17 2017/18 2% 5% 16% Offline Offline Offline Online Online Online 84% 98% 95% *All figures up to the end of May 18
INDIVIDUAL GIVING – Lottery investment GROSS INCOME* £194K 47% growth year on year NET INCOME* -£190K 900% increase in spend year on year *All figures up to the end of May 18
INDIVIDUAL GIVING – Lottery investment Gross Income through acquisition* Income % Increase Year on Year £77,000 Phone 381% Phone £32,000 Online 1500% Online £0 £20,000 £40,000 £60,000 £80,000 £100,000 0% 500% 1000% 1500% 2000% *All figures up to the end of May 18
The future is bright… the future is purple 1
2016 – 17 Financial Performance Harriet Jones Director of Finance and Resources
Overall financial performance £000’s 2014-15 2015-16 2016-17 Income 7,973 8,762 7,950 Expenditure 7,496 9,292* 7,139 Surplus/(deficit) 477 (530) 811 Investment gain / (loss) (229) 1,467 315 Net surplus 248 937 1,126 * Includes investment in Asthma UK Centre in Allergic Mechanisms of Asthma
Income £000’s 2014-15 2015-16 2016-17 Individuals 2,404 2,430 2,108 Companies and Trusts 872 688 710 Community and Events 1,333 1,214 1,347 Legacies 3,059 3,697 3,041 Other Income 305 502 460 Gifts in Kind - 231 284 Total 7,973 8,762 7,950
Income sources (gross)…..
… with costs of fundraising
Spend £000’s 2014-15 2015-16 2016-17 Research 1,557 3,688 1,496 Improving care 1,312 905 798 Advice and support 2,293 2,507 2,579 Fundraising 2,290 2,171 2,266 Investment management 44 21 - Total expenditure 7,496 9,292 7,139 * Includes Governance
Reserves
Recommend
More recommend
